Fact sheet: AXA Framlington Health

Fund information

Fund name
AXA Framlington Health Z Inc
Fund company manager
AXA IM UK
Fund type
UKA
Fund manager
Mark Hargraves
since 01/08/2014
Fund objective
The aim of this Fund is to provide long-term capital growth.
Benchmark
MSCI World Healthcare
Investment style
Growth
Investment method
Shares

Performance snapshot

Quick stats

1 Year return

29.01 %

1 Year rank in sector

38/106

Sector

UT Specialist

Yield

0.34

Fund size

£ 574.9 m

FE Risk score

137

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • North America
    67.99%
  • Europe ex UK
    15.13%
  • UK
    9.89%
  • Money Market
    3.43%
  • Japan
    2.66%
  • Pharmaceuticals
    29.78%
  • Biotechnology/Medical
    25.79%
  • Health Care
    19.49%
  • Healthcare & Medical Products
    17.06%
  • Money Market
    3.43%
  • North American Equities
    67.99%
  • Europe ex UK Equities
    15.13%
  • UK Equities
    9.89%
  • Money Market
    3.43%
  • Japanese Equities
    2.66%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund7.74 %13.16 %29.01 %65.35 %140.49 %
Sector0.51 %5.85 %18.47 %19.77 %38.19 %
Rank within sector2 / 10818 / 10638 / 1066 / 996 / 84
Quartile th1 st1 st2 nd1 st1 st

Calendar performance

YTD-20172016201520142013
Fund12.07 %7.81 %12.24 %29.57 %34.56 %
Sector4.25 %22.72 %-4.47 %1.15 %4.5 %
Rank within sector12 / 10676 / 1055 / 1015 / 972 / 87
Quartile th1 st3 rd1 st1 st1 st

Risk statistics

Alpha10.75
Beta0.78
Sharpe0.88
Volatility14.48
Tracking error12.46
Information ratio0.66
R-Squared0.27

Price movement

52 week high128.1
52 week low98.99
Current bid price0
Current offer price0
Current mid price128.1

Holdings by region

  • 67.99% North America
  • 15.13% Europe ex UK
  • 9.89% UK
  • 3.43% Money Market
  • 2.66% Japan
  • 0.9% Global Emerging Markets

Holdings by sector

  • 29.78% Pharmaceuticals
  • 25.79% Biotechnology/Medical
  • 19.49% Health Care
  • 17.06% Healthcare & Medical Products
  • 3.43% Money Market
  • 1.71% Hospital
  • 1.43% Food & Drug Retailers
  • 1.31% Conglomerates

Holdings by asset type

  • 67.99% North American Equities
  • 15.13% Europe ex UK Equities
  • 9.89% UK Equities
  • 3.43% Money Market
  • 2.66% Japanese Equities
  • 0.9% Global Emerging Market Equities

Individual holdings

  • 5.2% ROCHE HLDG AG
  • 4.8% UNITEDHEALTH GROUP INC
  • 4.7% GLAXOSMITHKLINE
  • 4.5% ALLERGAN PLC
  • 4.2% CELGENE CORP
  • 3.7% GILEAD SCIENCES INC
  • 3.6% MEDTRONIC INC
  • 2.8% LILLY (ELI) & CO
  • 2.7% THERMO FISHER SCIENTIFIC INC
  • 2.5% SHIRE PLC